<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33749521</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8635</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Autophagy</Title><ISOAbbreviation>Autophagy</ISOAbbreviation></Journal><ArticleTitle>Modulation of the IGF1R-MTOR pathway attenuates motor neuron toxicity of human ALS SOD1<sup>G93A</sup> astrocytes.</ArticleTitle><Pagination><StartPage>4029</StartPage><EndPage>4042</EndPage><MedlinePgn>4029-4042</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15548627.2021.1899682</ELocationID><Abstract><AbstractText>ALS (amyotrophic lateral sclerosis), the most common motor neuron disease, causes muscle denervation and rapidly fatal paralysis. While motor neurons are the most affected cells in ALS, studies on the pathophysiology of the disease have highlighted the importance of non-cell autonomous mechanisms, which implicate astrocytes and other glial cells. In ALS, subsets of reactive astrocytes lose their physiological functions and become toxic for motor neurons, thereby contributing to disease pathogenesis. Evidence of astrocyte contribution to disease pathogenesis are well established in cellular and animal models of familial ALS linked to mutant SOD1, where astrocytes promote motor neuron cell death. The mechanism underlying astrocytes reactivity in conditions of CNS injury have been shown to involve the MTOR pathway. However, the role of this conserved metabolic signaling pathway, and the potential therapeutic effects of its modulation, have not been investigated in ALS astrocytes. Here, we show elevated activation of the MTOR pathway in human-derived astrocytes harboring mutant SOD1, which results in inhibition of macroautophagy/autophagy, increased cell proliferation, and enhanced astrocyte reactivity. We demonstrate that MTOR pathway activation in mutant SOD1 astrocytes is due to post-transcriptional upregulation of the IGF1R (insulin like growth factor 1 receptor), an upstream positive modulator of the MTOR pathway. Importantly, inhibition of the IGF1R-MTOR pathway decreases cell proliferation and reactivity of mutant SOD1 astrocytes, and attenuates their toxicity to motor neurons. These results suggest that modulation of astrocytic IGF1R-MTOR pathway could be a viable therapeutic strategy in SOD1 ALS and potentially other neurological diseases.<b>Abbreviations:</b> ACM: astrocyte conditioned medium; AKT: AKT serine/threonine kinase; ALS: amyotrophic lateral sclerosis; BrdU: thymidine analog 5-bromo-2'-deoxyuridine; CNS: central nervous system; EIF4EBP1/4EBP1: eukaryotic translation initiation factor 4E binding protein 1; GFAP: glial fibrillary acidic protein; IGF1R: insulin like growth factor 1 receptor; INSR: insulin receptor; iPSA: iPSC-derived astrocytes; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta;MTOR: mechanistic target of rapamycin kinase; NES: nestin; PPK1: 3-phosphoinositide dependent protein kinase 1; PI: propidium iodide; PPP: picropodophyllotoxin; PTEN: phosphatase and tensin homolog; S100B/S100&#x3b2;: S100 calcium binding protein B; SLC1A3/ EAAT1: solute carrier family 1 member 3; SMI-32: antibody to nonphosphorylated NEFH; SOD1: superoxide dismutase 1; TUBB3: tubulin beta 3 class III; ULK1: unc-51 like autophagy activating kinase 1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Granatiero</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayles</LastName><ForeName>Nicole M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savino</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Csaba</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kharas</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-1165-6991</Identifier><AffiliationInfo><Affiliation>Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamata</LastName><ForeName>Hibiki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0020-6933</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS062055</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Autophagy</MedlineTA><NlmUniqueID>101265188</NlmUniqueID><ISSNLinking>1554-8627</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000597236">IGF1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="Y">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017526" MajorTopicYN="N">Receptor, IGF Type 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Astrocytes</Keyword><Keyword MajorTopicYN="N">EIF4EBP1</Keyword><Keyword MajorTopicYN="N">IGF1R</Keyword><Keyword MajorTopicYN="N">PPP</Keyword><Keyword MajorTopicYN="N">SOD1G93A</Keyword><Keyword MajorTopicYN="N">Torin1</Keyword><Keyword MajorTopicYN="N">ULK1</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">motor neurons</Keyword><Keyword MajorTopicYN="N">mtor</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>22</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33749521</ArticleId><ArticleId IdType="pmc">PMC8726657</ArticleId><ArticleId IdType="doi">10.1080/15548627.2021.1899682</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Laplante M, Sabatini DM.. MTOR signaling at a glance. J Cell Sci. 2009;122(Pt 20):3589&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758797</ArticleId><ArticleId IdType="pubmed">19812304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N. Autophagy: process and function. Genes Dev. 2007;21(22):2861&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kundu M, Viollet B, et al. AMPK and MTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987946</ArticleId><ArticleId IdType="pubmed">21258367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Sarbassov DD, Ali SM, et al. MTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150925</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinzalla V, Stracka D, Oppliger W, et al. Activation of MTORC2 by association with the ribosome. Cell. 2011;144(5):757&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376236</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplante M, Sabatini DM. MTOR signaling in growth control and disease. Cell. 2012;149(2):274&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331679</ArticleId><ArticleId IdType="pubmed">22500797</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16(5):249&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253239</ArticleId><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson JA. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics. 2010;7(4):471&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967019</ArticleId><ArticleId IdType="pubmed">20880509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosunov AA, Wu X, Weiner HL, et al. Tuberous sclerosis: a primary pathology of astrocytes? Epilepsia. 2008;49(Suppl 2):53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18226172</ArticleId></ArticleIdList></Reference><Reference><Citation>Codeluppi S, Svensson CI, Hefferan MP, et al. The Rheb-MTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. J Neurosci. 2009;29(4):1093&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682457</ArticleId><ArticleId IdType="pubmed">19176818</ArticleId></ArticleIdList></Reference><Reference><Citation>He M, Shi X, Yang M, et al. Mesenchymal stem cells-derived IL-6 activates AMPK/MTOR signaling to inhibit the proliferation of reactive astrocytes induced by hypoxic-ischemic brain damage. Exp Neurol. 2019;311:15&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">30213506</ArticleId></ArticleIdList></Reference><Reference><Citation>Granatiero V, Konrad C, Bredvik K, et al. Nrf2 signaling links ER oxidative protein folding and calcium homeostasis in health and disease. Life Sci Alliance. 2019;2(5):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819749</ArticleId><ArticleId IdType="pubmed">31658977</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140(3):313&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852113</ArticleId><ArticleId IdType="pubmed">20144757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaizuka T, Morishita H, Hama Y, et al. An autophagic flux probe that releases an internal control. Mol Cell. 2016;64(4):835&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">27818143</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of MTORC1. J Biol Chem. 2009;284(12):8023&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2658096</ArticleId><ArticleId IdType="pubmed">19150980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CK, Murata K, Walz T, et al. Structure of the human MTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010;38(5):768&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887672</ArticleId><ArticleId IdType="pubmed">20542007</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux PP, Topisirovic I. Regulation of mRNA translation by signaling pathways. Cold Spring Harb Perspect Biol. 2012;4:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536343</ArticleId><ArticleId IdType="pubmed">22888049</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Gravel S-P, Hulea L, et al. MTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle. 2015;14(4):473&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615141</ArticleId><ArticleId IdType="pubmed">25590164</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Nav&#xe9; BT, Ouwens DM, Withers DJ, et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344(Pt 2):427&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220660</ArticleId><ArticleId IdType="pubmed">10567225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60(13):3504&#x2013;3513.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910062</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbassov DD, et al. Phosphorylation and regulation of Akt/PKB by the rictor-MTOR complex. Science. 2005;307(5712):1098&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710138</ArticleId><ArticleId IdType="pubmed">18767981</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon S, Dibble C, Talbott G, et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of MTORC1 at the lysosome. Cell. 2014;156(4):771&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030681</ArticleId><ArticleId IdType="pubmed">24529379</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning BD, Tee AR, Logsdon MN, et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10(1):151&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150915</ArticleId></ArticleIdList></Reference><Reference><Citation>Menting JG, Lawrence C, Kong G-W, et al. Structural congruency of ligand binding to the insulin and insulin/type 1 insulin-like growth factor hybrid receptors. Structure. 2015;23(7):1271&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">26027733</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilcanu D, Girnita A, Girnita L, et al. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene. 2004;23(47):7854&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15334055</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellows AD, Rhymes ER, Gibbs KL, et al. IGF 1R regulates retrograde axonal transport of signalling endosomes in motor neurons. EMBO Rep. 2020;21(3):e49129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054680</ArticleId><ArticleId IdType="pubmed">32030864</ArticleId></ArticleIdList></Reference><Reference><Citation>Blizzard CA, Lee KM, Dickson TC. Inducing chronic excitotoxicity in the mouse spinal cord to investigate lower motor neuron degeneration. Front Neurosci. 2016;10:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773442</ArticleId><ArticleId IdType="pubmed">26973454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatini DM. Twenty-five years of MTOR: uncovering the link from nutrients to growth. Proc Natl Acad Sci U S A. 2017;114(45):11818&#x2013;11825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5692607</ArticleId><ArticleId IdType="pubmed">29078414</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiech L, Perycz M, Malik A, et al. Role of MTOR in physiology and pathology of the nervous system. Biochim Biophys Acta. 2008;1784(1):116&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">17913600</ArticleId></ArticleIdList></Reference><Reference><Citation>Switon K, et al. Molecular neurobiology of MTOR. Neuroscience. 2017;341:112&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">27889578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li L, Chen S, et al. Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7(4):412&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Roselli F, Singh K, et al. Neuroprotection through excitability and MTOR required in ALS motoneurons to delay disease and extend survival. Neuron. 2013;80(1):80&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24094105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Tsai KJ, Shen CK. Autophagy activation ameliorates neuronal pathogenesis of FTLD-U mice: a new light for treatment of TARDBP/TDP-43 proteinopathies. Autophagy. 2013;9(2):239&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552888</ArticleId><ArticleId IdType="pubmed">23108236</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamenter ME, Perkins GA, McGinness AK, et al. Autophagy and apoptosis are differentially induced in neurons and astrocytes treated with an in vitro mimic of the ischemic penumbra. PLoS One. 2012;7(12):e51469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520810</ArticleId><ArticleId IdType="pubmed">23251543</ArticleId></ArticleIdList></Reference><Reference><Citation>Moruno-Manchon JF, Uzor N-E, Ambati CR, et al. Sphingosine kinase 1-associated autophagy differs between neurons and astrocytes. Cell Death Dis. 2018;9(5):521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943283</ArticleId><ArticleId IdType="pubmed">29743513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni A, et al. Differential regulation of autophagy during metabolic stress in astrocytes and neurons. Autophagy. 2019;1&#x2013;17.</Citation></Reference><Reference><Citation>Nieto Guil AF, Oksdath M, Weiss LA, et al. IGF-1 receptor regulates dynamic changes in neuronal polarity during cerebral cortical migration. Sci Rep. 2017;7(1):7703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550468</ArticleId><ArticleId IdType="pubmed">28794445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosa L, Dupraz S, Laurino L, et al. IGF-1 receptor is essential for the establishment of hippocampal neuronal polarity. Nat Neurosci. 2006;9(8):993&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16845384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301(5634):839&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Giacinti C, Pelosi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol. 2005;168(2):193&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71(22):1770&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2617770</ArticleId><ArticleId IdType="pubmed">19029516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Serafini M, Prelle A, et al. Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle Nerve. 2012;45(2):200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306791</ArticleId><ArticleId IdType="pubmed">22246875</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilczak N, De Vos RA, De Keyser J. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet. 2003;361(9362):1007&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YH, Joo KM, Shin CM, et al. Immunohistochemical study on the distribution of insulin-like growth factor I (IGF-I) receptor in the central nervous system of SOD1(G93A) mutant transgenic mice. Brain Res. 2003;994(2):253&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, et al. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399(p):217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauner K, Eid W, Raghupathy R, et al. MTOR complex 1 activity is required to maintain the canonical endocytic recycling pathway against lysosomal delivery. J Biol Chem. 2017;292(14):5737&#x2013;5747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392569</ArticleId><ArticleId IdType="pubmed">28196862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvainickas A, et al. Cargo-selective SNX-BAR proteins mediate retromer trimer independent retrograde transport. J Cell Biol. 2017;216(11):3677&#x2013;3693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674888</ArticleId><ArticleId IdType="pubmed">28935632</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, et al. Gene profiling of human induced pluripotent stem cell-derived astrocyte progenitors following spinal cord engraftment. Stem Cells Transl Med. 2014;3(5):575&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006486</ArticleId><ArticleId IdType="pubmed">24604284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>